TCR-engineered T Cells in NSCLC and HNSCC Patients (ACTengine)
Status:
Not yet recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This clinical research study investigates IMA201 which is composed of special immune cells (T
cells, also called T lymphocytes) being genetically modified by introduction of a
tumor-antigen specific T cell receptor (TCR) to fight against cancer. Patients that choose to
take part in this study have advanced cancer where there is no (further) standard treatment
for their cancer available OR current treatments are not tolerated.
The main purpose of this clinical research study is to confirm the safety of IMA201 and to
define the highest safe dose of IMA201 cells to give to patients. The study will also
investigate what the specific side effects of this treatment are, and to see whether this
therapy shows clinical activity in patients with their advanced cancer.